A systematic review finds metabolic bariatric surgery reduces AMH levels in women, suggesting implications for fertility.
The possible anti-Mullerian hormone (AMH)-reduction impact of metabolic bariatric surgery has been assessed in a number of interventional investigations. The outcomes are still incongruous, however. This research sought to thoroughly examine the effects of metabolic bariatric surgery on AMH in order to have a better understanding of them. Using standard keywords, the Scopus, PubMed/Medline, Web of Science, Cochrane, and Embase databases were searched to find all eligible human studies, including observational cohorts and single-arm pre–post studies, examining the levels of AMH after metabolic bariatric surgery treatment. For the best result estimate, random-effects model analysis produced 95% confidence intervals and a pooled weighted mean difference. This article includes 15 treatment arms with a total of 459 participants. The results from the random-effects meta-analysis showed a significant reduction in AMH levels in the included observational and pre–post studies, with a pooled weighted mean difference (WMD) of −0.58 ng/ml [95% confidence interval (CI): −1.10 to −0.06; p = 0.028]. Subgroup analysis indicated that metabolic bariatric surgery had a greater effect on AMH reduction in the population with PCOS, with a time after the intervention of 48 weeks or longer, and in participants aged 30 years or younger compared to other groups. This meta-analysis suggests that metabolic bariatric surgery is associated with reductions in AMH, particularly in women with PCOS. However, due to high heterogeneity, low-quality evidence, and lack of fertility outcomes, these results should be interpreted with caution. The implications for fertility remain uncertain.
No takes yet. Share an insight, caveat, or question.
Roshan et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: